Skip to main content
Study examines kidney outcomes in diabetes patients on empagliflozin
1/11/2019

A study in the Journal of Diabetes Investigation showed that 15.5% and 13.7% of Asian adults with type 2 diabetes and cardiovascular disease who received empagliflozin had worsening nephropathy and progressed to macroalbuminuria, respectively, compared with 21.8% and 19.3% of those on placebo. Japanese researchers conducted a post hoc analysis of 1,517 diabetes patients from the EMPA-REG OUTCOME study and found that the empagliflozin group also had an increased estimated glomerular filtration rate over 192 weeks and a reduced urine albumin to creatinine ratio at weeks 12 through 164.

Full Story: